Gender-affirming hormone treatment modalities for transfemale & non-binary transfeminine individuals: A UK perspective. [Review]

Sagar, RC.; Millson-Brown, V.

Gender-affirming hormone treatment modalities for transfemale & non-binary transfeminine individuals: A UK perspective. [Review]

All Authors

Sagar, RC.

Millson-Brown, V.

LTHT Author

Sagar, Rebecca

LTHT Department

Doctors' Rotation

Publication Date

2024

Item Type

Journal Article
Review

Abstract

Gender incongruence and the number of people seeking gender affirming hormone treatment has dramatically risen in the last two decades. In the UK, transgender women and non-binary transfeminine individuals are typically treated with simultaneous suppression of endogenous testosterone production through anti-androgens and exogenous oestradiol replacement. Oestrogen replacement comes in different forms and is primarily given as transdermal (gel or patch) or oral preparations in the UK. Decisions around preparation choice are based on a combination of individual preference and/or mitigating the chance of complications based on individual risk profiles. Time frames to achieve female physical changes are largely predictable and managing expectations of individuals prior to commencing treatment is highly important. Common complications include venous thromboembolism, liver dysfunction and effects on fertility, thus individuals should be thoroughly counselled prior to commencing treatment. This article provides an overview of the management and considerations of gender-affirming hormone treatment in transgender women and non-binary transfeminine individuals. Crown